| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG as meets exclusion criteria 6. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information. |
|
Medicine details |
|
| Medicine name | fluticasone propionate/salmeterol (AirFluSal® Forspiro®) |
| Formulation | 500 mcg/50 mcg inhalation powder |
| Reference number | 2678 |
| Indication | Symptomatic treatment of adult patients with COPD, with a FEV1 < 60% predicted normal (pre-bronchodilator) and a history of repeated exacerbations, who have significant symptoms despite regular bronchodilator therapy |
| Company | Sandoz Ltd |
| BNF chapter | Respiratory system |
| Submission type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 12/11/2015 |